Kalantarinia Kambiz, Siragy Helmy M
Department of Medicine, Division of Endocrinology & Metabolism, Box 800746, University of Virginia Health System, Charlottesville, VA 22908-0746, USA.
Curr Diab Rep. 2002 Oct;2(5):423-30. doi: 10.1007/s11892-002-0107-1.
Affecting over 16 million individuals, diabetes mellitus is among the leading causes of mortality in the United States. Hypertension is a common finding among diabetic patients and increases their morbidity and mortality. Control of blood pressure in this population has been shown to improve outcomes. Recent randomized trials have proven the benefit of lower blood pressure goals in the treatment of hypertensive patients as compared with nondiabetic patients. Randomized controlled trials have also demonstrated that the selection of the antihypertensive agent used to treat hypertension in diabetic patients is as important as the reduction of blood pressure levels to the recommended levels. In this article, we first focus on the importance of the renin angiotensin system in the development of diabetic complications, and then we review the results of the recent studies that have had a major impact on the treatment of hypertension in diabetes.
糖尿病影响着超过1600万人,是美国主要的死亡原因之一。高血压在糖尿病患者中很常见,会增加他们的发病率和死亡率。已证明控制该人群的血压可改善预后。最近的随机试验已证实,与非糖尿病患者相比,降低血压目标值对高血压患者的治疗有益。随机对照试验还表明,选择用于治疗糖尿病患者高血压的抗高血压药物与将血压水平降至推荐水平同样重要。在本文中,我们首先关注肾素血管紧张素系统在糖尿病并发症发生发展中的重要性,然后回顾最近对糖尿病高血压治疗产生重大影响的研究结果。